The piece covers potential treatments for dementia and muscular dystrophy with engineered human cells.
19.05.2021
bit.bio’s Mark Kotter: “A single cell to feed the world”
bit.bio CEO and founder Dr Mark Kotter was a speaker on the podcast Danny in the Valley.
Inside the breakthrough that could take lab-grown meat from the lab to the supermarket
Featured on Massive Science: how bit.bio's breakthrough opti-ox™ technology is being used by cultured meat company Meatable.
bit.bio wins Biotech Company of the Year at the Cambridge Independent Science and Technology awards
bit.bio wins Biotech Company of the Year at the Cambridge Independent Science andTechnology awards.
Meet the company reprogramming the future of synthetic biology
SynbioBeta CEO John Cumbers talks reimagining cell therapies through cell reprogramming with Rick Klausner and bit.bio CEO.
Sitting down with… bit.bio
Dr Farah Patell-Socha, VP of Research Products discusses the launch of ioSkeletal Myocytes.
Q&A with Dr Mark Kotter: Transforming drug discovery & medical research
IBI Journal Q&A with Dr Mark Kotter who talks about producing every human cell type at scale.
Can we recreate every human cell type in the body? This UK startup thinks so
bit.bio and the London Institute of Mathematical Sciences (LIMS) want to recreate every human cell type.
British firm cracks code for stem cells
bit.bio receives £40m of backing for technology that it claims can reliably reprogram stem cells.